Drug Profile
Batiraxcept - Aravive
Alternative Names: 3D-229; 3D-299; Aravive-S6; AVB 500; AVB S6 500; Axl fc fusion protein AVB-S6-500; Ruga-S6; S6-500cLatest Information Update: 09 Nov 2023
Price :
$50
*
At a glance
- Originator Stanford University
- Developer 3D Medicines; Aravive; Aravive Biologics; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group
- Class Antifibrotics; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase II IgA nephropathy; Renal fibrosis; Urogenital cancer
- Phase I/II Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma
- Phase I Unspecified
- Preclinical Cholangiocarcinoma
- No development reported Acute myeloid leukaemia; Solid tumours
- Discontinued Viral infections
Most Recent Events
- 09 Nov 2023 Aravive terminates the phase III AXLerate-OC PROC trial in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in the USA, Belgium, Canada, China, Czech republic, France, Georgia, Greece, Italy, Poland, Spain, United Kingdom, Germany (IV) due to no significant differences observed in median PFS (NCT04729608) (EudraCT2021-000293-28)
- 26 Oct 2023 Aravive terminates a phase I/II trial in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) due to business reasons (NCT04300140)
- 14 Aug 2023 Aravive terminates a phase-I/II trial in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (IV) due to business reasons(NCT04983407)